« REGULATOR DEEMED INDY-MAC BANK "WELL CAPITALIZED" BEFORE COLLAPSE | Main | RE-POST: MOTH-LIKE AGENCIES MORPH INTO "NEW DEAL" ECONOMIC POLLINATORS »

September 23, 2009

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

fso

By the time morphine starts being administered, the end is near.
This study could be very significant in that it would affect trials of anti-cancer drugs on late stage patients. Discarded therapies many have to be re-evaluated as will existing therapies in the presence of non-opiates.
fso301

rockingham

This result further supports the use of low dose naltrexone as an opiate receptor antagonist in cancer treatment.

http://www.lowdosenaltrexone.org/ldn_and_cancer.htm
by Rockingham

wayne lusvardi

From Wikipedia on Urokinase

The most important inhibitors of urokinase are the serpins plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), which inhibits the protease activity irreversibly.

Urokinase and Cancer

Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation, facilitates tissue invasion and thus contributes to metastasis. This makes urokinase an attractive drug target and inhibitors have been sought to be used as anticancer agents. However incompatibilities between the human and murine system hampers clinical evaluation of these agents. Through its interaction with the urokinase receptor, urokinase affects several other aspects of cancer biology such as cells adhesion, migration and cellular mitotic pathways.

Mike Jones

Thanks for the interesting article!

The comments to this entry are closed.

December 2011

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
Blog powered by Typepad

Twitter Updates

    follow me on Twitter